行情

MNKD

MNKD

曼恩凯德生物医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.205
+0.025
+2.12%
已收盘, 16:10 11/20 EST
开盘
1.180
昨收
1.180
最高
1.240
最低
1.170
成交量
249.24万
成交额
--
52周最高
2.340
52周最低
0.9400
市值
2.49亿
市盈率(TTM)
-4.6796
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MNKD 新闻

  • Edited Transcript of MNKD earnings conference call or presentation 6-Nov-19 2:00pm GMT
  • Thomson Reuters StreetEvents.4天前
  • MannKind Corporation 2019 Q3 - Results - Earnings Call Presentation
  • Seeking Alpha - Article.11/13 16:05
  • Introducing MannKind (NASDAQ:MNKD), The Stock That Collapsed 96%
  • Simply Wall St..11/12 19:26
  • Assessing MannKind's Q3 - What Investors Need To Know
  • Seeking Alpha - Article.11/10 19:03

更多

所属板块

生物技术和医学研究
+0.65%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

MNKD 简况

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
展开

Webull提供MannKind Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。